January 2020
Hearings, Briefings, Meetings
September 9 – Representative David Trone and other members of the Freshman Working Group on Addiction toured Dr. Nora Volkow’s laboratory at the NIH Clinical Center.
October 11, 2019 – Dr. Volkow briefed Consumer Policy Subcommittee staff of the House Committee on Oversight and Government Reform on kratom.
October 23, 2019 – Dr. Volkow participated in a Senate Caucus on Narcotics Control Hearing titled "Marijuana and America’s Health: Questions and Issues for Policy Makers."
December 12, 2019 – Dr. Volkow briefed the House Freshman Working Group on Addiction on methamphetamine use and NIDA research to address it.
Wednesday, December 18 – Dr. Volkow conducted a telebriefing on the FY 2019 Monitoring the Future (MTF) survey results for Congressional staff. She was joined by MTF Principal Investigator Dr. Richard Miech.
January 15, 2019 – Dr. Volkow testified before the House Energy and Commerce Health Subcommittee at a hearing titled "Cannabis Policies for the New Decade."
Legislation of Interest
- A number of bills relevant to marijuana research have been introduced in Congress.
- The Senate passed the "Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act," which would extend the temporary placement of fentanyl-related substances into Schedule I of the Controlled Substances Act (CSA) until May 6, 2021 and require the Government Accountability Office to conduct a study of the class control of fentanyl-related substances, including the processes to obtain or modify a registration under the CSA to conduct research with these substances.
May 2020
Hearings, Briefings, Meetings
March 4, 2020 – Dr. Volkow joined Dr. Collins and other NIH IC Directors to testify before the House LHHS Appropriations Subcommittee on the FY 2021 NIH budget.
April 1, 2020 – Dr. Volkow briefed Representative David Trone on the challenges to conducting research with marijuana and other Schedule I drugs.
September 2020
Hearings, Briefings, Meetings
August 3, 2020 - Dr. Volkow briefed U.S. Senate Health, Education, Labor and Pensions (HELP) Committee staff on stimulant use disorder treatments.